[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613549":3},{"organization":4,"armGroups":7,"interventions":48,"overallOfficials":54,"centralContacts":79,"locations":85,"responsibleParty":124,"collaborators":54,"id":126,"slug":127,"hasResults":128,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":54,"eligibilityCriteria":132,"healthyVolunteers":128,"sex":133,"minAge":134,"maxAge":135,"enrollmentInfo":136,"targetDuration":54,"studyType":139,"phases":140,"briefSummary":142,"conditions":143,"keywords":54,"overallStatus":88,"whyStopped":54,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},{"fullName":5,"class":6},"Shanghai Hengrui Pharmaceutical Co., Ltd.","INDUSTRY",[8,15,20,27,31,35,40,44],{"label":9,"type":10,"description":11,"interventionNames":12},"SHR-7787 combined with SHR-1316","EXPERIMENTAL","SHR-7787 injection combined with SHR-1316 injection.",[13,14],"Drug: SHR-7787 Injection","Drug: SHR-1316 Injection",{"label":16,"type":10,"description":17,"interventionNames":18},"SHR-7787 combined with SHR-4849","SHR-7787 injection combined with SHR-4849 injection.",[13,19],"Drug: SHR-4849 Injection",{"label":21,"type":10,"description":22,"interventionNames":23},"SHR-7787 combined with etoposide and carboplatin\u002Fcisplatin","SHR-7787 injection combined with etoposide and carboplatin\u002Fcisplatin injection.",[13,24,25,26],"Drug: Etoposide injection","Drug: Carboplatin injection","Drug: Cisplatin injection",{"label":28,"type":10,"description":29,"interventionNames":30},"SHR-7787 combined with SHR-1316, etoposide, carboplatin\u002Fcisplatin","SHR-7787 injection combined with SHR-1316, etoposide, carboplatin\u002Fcisplatin injection.",[13,14,24,25,26],{"label":32,"type":10,"description":33,"interventionNames":34},"SHR-7787 combined with SHR-4849 and SHR-1316","SHR-7787 injection combined with SHR-4849 and SHR-1316 injection.",[13,14,19],{"label":36,"type":10,"description":37,"interventionNames":38},"SHR-7787 combined with SHR-1316 and BP102","SHR-7787 injection combined with SHR-1316 and BP102 injection.",[13,14,39],"Drug: BP102 Injection",{"label":41,"type":10,"description":42,"interventionNames":43},"SHR-7787 combined with SHR-4849 and BP102","SHR-7787 injection combined with SHR-4849 and BP102 injection.",[13,19,39],{"label":45,"type":10,"description":46,"interventionNames":47},"SHR-7787 combined with SHR-4849, SHR-1316 and carboplatin\u002Fcisplatin","SHR-7787 injection combined with SHR-4849, SHR-1316 and carboplatin\u002Fcisplatin injection.",[13,14,19,25,26],[49,55,59,63,67,71,75],{"type":50,"name":51,"description":52,"armGroupLabels":53,"otherNames":54},"DRUG","SHR-7787 Injection","SHR-7787 Injection.",[9,36,28,16,41,32,45,21],null,{"type":50,"name":56,"description":57,"armGroupLabels":58,"otherNames":54},"SHR-1316 Injection","SHR-1316 Injection.",[9,36,28,32,45],{"type":50,"name":60,"description":61,"armGroupLabels":62,"otherNames":54},"SHR-4849 Injection","SHR-4849 Injection.",[16,41,32,45],{"type":50,"name":64,"description":65,"armGroupLabels":66,"otherNames":54},"Etoposide injection","Etoposide Injection.",[28,21],{"type":50,"name":68,"description":69,"armGroupLabels":70,"otherNames":54},"Carboplatin injection","Carboplatin Injection.",[28,45,21],{"type":50,"name":72,"description":73,"armGroupLabels":74,"otherNames":54},"Cisplatin injection","Cisplatin Injection.",[28,45,21],{"type":50,"name":76,"description":77,"armGroupLabels":78,"otherNames":54},"BP102 Injection","BP102 Injection.",[36,41],[80],{"name":81,"role":82,"phone":83,"phoneExt":54,"email":84},"Xianhua Qiu","CONTACT","+86-0518-82342973","xianhua.qiu@hengrui.com",[86,107],{"facility":87,"status":88,"city":89,"state":90,"zip":91,"country":92,"countryCode":93,"cosmosGeoPoint":94,"geoPoint":99,"contacts":100},"Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology","RECRUITING","Wuhan","Hubei","430030","China","CN",{"type":95,"coordinates":96},"Point",[97,98],114.26667,30.58333,{"lat":98,"lon":97},[101,105],{"name":102,"role":82,"phone":103,"phoneExt":54,"email":104},"Qian Chu","+86-027-83663147","qchu@hust.edu.cn",{"name":102,"role":106,"phone":54,"phoneExt":54,"email":54},"PRINCIPAL_INVESTIGATOR",{"facility":108,"status":88,"city":109,"state":110,"zip":111,"country":92,"countryCode":93,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Shanghai Pulmonary Hospital","Shanghai","Shanghai Municipality","200433",{"type":95,"coordinates":113},[114,115],121.45806,31.22222,{"lat":115,"lon":114},[118,123],{"name":119,"role":82,"phone":120,"phoneExt":121,"email":122},"Shengxiang Ren","+86-021-65115006","3051","arry_ren@126.com",{"name":119,"role":106,"phone":54,"phoneExt":54,"email":54},{"type":125,"investigatorFullName":54,"investigatorTitle":54,"investigatorAffiliation":54,"oldNameTitle":54,"oldOrganization":54},"SPONSOR","100613549","phase-2-a-trial-of-shr-7787-injection-combined-with-other-anti-tumor-drugs-in-patients-with-malignant-solid-tumors-100613549",false,"NCT07268040","A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors","A Multicenter, Open-label Phase II Clinical Study of SHR-7787 Combined With Other Antitumor Drugs in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Ability to understand and voluntarily agrees to participate by giving written informed consent for the study;\n2. Patients with histologically or cytologically confirmed unresectable solid tumors;\n3. At least one measurable lesion was identified per RECIST 1.1;\n4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1;\n5. Adequate organ functions as defined per protocol;\n6. Minimum life expectancy of 3 months.\n\nExclusion Criteria:\n\n1. Patients with known active central nervous system (CNS) metastases;\n2. History of other malignancy within the past 5 years, with exceptions defined in the protocol;\n3. Patients with uncontrolled cancer pain;\n4. Patients with serious cardiovascular and\u002For cerebrovascular diseases;\n5. Uncontrollable third-space effusion, such as pleural effusion, pericardial effusion or peritoneal effusion;\n6. Patients with Severe infections within 4 weeks prior to the first dose;\n7. Active pulmonary tuberculosis infection;\n8. History of immunodeficiency;\n9. History of autoimmune diseases;\n10. The adverse events of previous antineoplastic therapy did not recover to CTCAE≤ grade 1;\n11. Pregnant or nursing women, or planned to become pregnant during the study period;\n12. Known allergic to any component of investigational drugs.","ALL","18 Years","75 Years",{"count":137,"type":138},400,"ESTIMATED","INTERVENTIONAL",[141],"PHASE2","This study aims to evaluate the safety, tolerability and efficacy of SHR-7787 in combination with other anti-tumor drugs in patients with malignant solid tumors.",[144],"Malignant Solid Tumors","2026-01-08",{"date":147,"type":148},"2026-01-12","ACTUAL",{"date":150,"type":148},"2025-12-23",{"date":152,"type":138},"2028-12",{"name":5,"class":6},2]